Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

Launched by CEDARS-SINAI MEDICAL CENTER · Dec 13, 2007

Keywords

ClinConnect Summary

This clinical trial is studying how cardiac magnetic resonance imaging (CMR) can help understand small artery heart disease in women. Specifically, it aims to gather information from 40 healthy women, aged 35 to 65, who do not have any known heart disease or heart disease risk factors, such as high blood pressure or high cholesterol. By comparing the CMR results of these women to those with heart disease, researchers hope to improve the way small vessel heart disease is diagnosed and treated in women, who are often affected more severely than men.

If you or someone you know is interested in participating, you would first have a discussion with a research doctor about the CMR procedure. After agreeing to participate, you would fill out some health questionnaires, have a blood test to ensure your kidneys are working well (since a special dye will be used during the MRI), and then undergo the CMR scan. The entire process can be completed in one or two visits, and there’s no need for any follow-up appointments afterward. This study is important because it may lead to better, non-invasive ways to diagnose and treat heart disease in women, ultimately improving health outcomes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women without signs and symptoms of myocardial ischemia (chest pain, abnormal stress testing, abnormal noninvasive testing).
• • 2. No cardiac risk factors by Framingham/NCEP criteria, age and BMI matched to the Cardiac Syndrome X population, and a normal exercise stress test.
• Exclusion Criteria:
• • 1. Contraindications to CMR testing (metal devices in chest, claustrophobia, known angioedema).
• • 2. Contraindication to Adenosine or Lexiscan (regadenoson) including heart block (second and third degree) and sinus node disease, significant COPD/asthma, or systemic hypotension (\<90 mmHg).
• • 3. Contraindication to Dobutamine including severe systemic hypertension (≥ 220/120 mmHg), unstable angina, significant aortic valve stenosis, complex cardiac arrhythmia including uncontrolled atrial fibrillation, hypertrophic obstructive cardiomyopathy, myocarditis, endocarditis, pericarditis, or uncontrolled congestive heart failure.
• • 4. Contraindication to Gadolinium (renal impairment).
• • 5. Any renal disease.
• • 6. Pregnant and lactating women.
• • 7. Inability to perform exercise, eg. orthopedic limitations.
• • 8. Allergy to animal dander.